Navigation Links
Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation
Date:12/4/2007

NEW HAVEN, Conn., Dec. 4 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq Capital Market: VION) today announced the start of an investigator-sponsored Phase I clinical trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in combination with hematopoietic cell transplant (HCT) in patients with various advanced hematologic malignancies. The trial is being conducted under the direction of Roy Jones, M.D., Ph.D., a professor in the Department of Stem Cell Transplantation at The University of Texas M.D. Anderson Cancer Center.

The objective of the trial is to define the maximum tolerated dose (MTD) of Cloretazine(R) (VNP40101M) when given to patients of 18 to 65 years of age with poor-prognosis leukemia, lymphoma, and Hodgkin's disease who are undergoing either an allogeneic or autologous HCT.

Ann Cahill, Vice President of Clinical Development, commented, "Both patients and physicians are searching for ways to improve outcomes after stem cell transplantation. Patients with advanced disease are particularly in need of new therapies." Ms. Cahill concluded, "We are hopeful that Cloretazine(R) (VNP40101M) can make a contribution in the stem cell transplant setting."

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) as a single agent in small cell lung cancer, with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Form 10-K for the year ended December 31, 2006 and the Company's Form 10-Q for the quarter ended September 30, 2007. In particular, there can be no assurance as to the results of any of the Company's clinical trials, that any of these trials will continue to full accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to update arises under law when prior disclosure becomes materially misleading in light of subsequent events, Vion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

COMPANY CONTACT: Vion Pharmaceuticals, Inc.

Alan Kessman, Chief Executive Officer

Howard B. Johnson, President & CFO

(203) 498-4210


'/>"/>
SOURCE Vion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Australia Ophthalmic Lasers Market Outlook to 2022 Summary ... to 2022", provides key market data on the Australia ... of US dollars, volume (in units) and average prices ... and YAG Lasers. The report also provides company ... market segements, and global corporate-level profiles of the key ...
(Date:12/8/2016)...  The global biosurgery market is expected to grow ... of 2016 to 2021. The market is poised to ... billion in 2016. The market is primarily driven by ... injuries and spinal problems, increasing clearance of biosurgery products ... loss management. In this report, the biosurgery ...
(Date:12/8/2016)... 2016 KEY FINDINGS North ... the market in 2016 and is expected to continue ... to a large number of surgical procedures that are ... share in the patient temperature management market.) Patient warming ... loss of blood during surgeries, lowering the risks of ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... ... STAT courier is pleased to announce that due to customer demand, as well ... presence in Dallas. One of the most exciting parts for STAT is that the ... and Forth Worth market. STAT takes pride in treating their employees with integrity and ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... and the Affordable Care Act. Dr. Botelho advocates for the mass media launching ... movement gives people ongoing opportunities to share their unfortunate experiences; such a movement ...
(Date:12/8/2016)... Cincinnati, OH (PRWEB) , ... December 08, 2016 ... ... offering insurance and financial planning services from offices headquartered in Hamilton County, is ... animal rescue LuvFurMutts. , LuvFurMutts specializes in finding new homes for orphaned or ...
(Date:12/8/2016)... ... , ... Coppin Insurance Agency, an insurance and financial planning firm based in ... area, is embarking on a charity drive with the goal of providing support and ... Food Bank of Southwest Florida works to provide fresh and nutritious food free of ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... consultation services to families and business owners in and around central Kansas, is ... assistance to at-risk youth in the region. , Headquartered in Wichita, Youth Horizons ...
Breaking Medicine News(10 mins):